These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Dissecting super-enhancer driven transcriptional dependencies reveals novel therapeutic strategies and targets for group 3 subtype medulloblastoma. Li M; Han Y; Wang C; Kang W; Jiang W; Zhang L; Tang Y J Exp Clin Cancer Res; 2022 Oct; 41(1):311. PubMed ID: 36273157 [TBL] [Abstract][Full Text] [Related]
29. Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma. Shishido K; Purvis IJ; Velpula KK; Venkataraman S; Vibhakar R; Asuthkar S Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37114557 [TBL] [Abstract][Full Text] [Related]
30. RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Ćwiek P; Leni Z; Salm F; Dimitrova V; Styp-Rekowska B; Chiriano G; Carroll M; Höland K; Djonov V; Scapozza L; Guiry P; Arcaro A Oncotarget; 2015 Jan; 6(1):116-29. PubMed ID: 25402633 [TBL] [Abstract][Full Text] [Related]
31. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Spender LC; Inman GJ Mol Cancer Res; 2012 Mar; 10(3):347-59. PubMed ID: 22241218 [TBL] [Abstract][Full Text] [Related]
32. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Pei Y; Liu KW; Wang J; Garancher A; Tao R; Esparza LA; Maier DL; Udaka YT; Murad N; Morrissy S; Seker-Cin H; Brabetz S; Qi L; Kogiso M; Schubert S; Olson JM; Cho YJ; Li XN; Crawford JR; Levy ML; Kool M; Pfister SM; Taylor MD; Wechsler-Reya RJ Cancer Cell; 2016 Mar; 29(3):311-323. PubMed ID: 26977882 [TBL] [Abstract][Full Text] [Related]
33. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation. Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907 [TBL] [Abstract][Full Text] [Related]
34. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma. Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591 [TBL] [Abstract][Full Text] [Related]